Literature DB >> 1713846

The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment.

C S Lewin1, I Morrissey, J T Smith.   

Abstract

All 4-quinolones that have been examined display rapid bactericidal activity which is biphasic. At concentrations above the MIC, the lethality of the drugs increases until a concentration known as the optimum bactericidal concentration (OBC) beyond which the bactericidal activity then declines. The biphasic response appears to be due to the inhibition of RNA synthesis at concentrations above the OBC, as RNA synthesis is required for the full bactericidal activity of the 4-quinolones. However, differences in the biphasic response are observed as some fluoroquinolones are still able to kill bacteria in the absence of bacterial protein or RNA synthesis, thus reducing the inhibition of bactericidal activity at concentrations above the OBC. It has been proposed that this ability to kill bacteria in the absence of protein or RNA synthesis is due to the possession of an additional bactericidal mechanism by these fluoroquinolones. Oxygen also appears to be essential for the lethality of the clinically available 4-quinolones although it is not required for the drugs to inhibit bacterial multiplication. Therefore these drugs are not bactericidal under anaerobic conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713846     DOI: 10.1007/bf01966996

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  60 in total

1.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

2.  Reduced enteral absorption of ciprofloxacin in the presence of antacids.

Authors:  G Höffken; K Borner; P D Glatzel; P Koeppe; H Lode
Journal:  Eur J Clin Microbiol       Date:  1985-06       Impact factor: 3.267

3.  Survival of recombination-deficient mutants of Escherichia coli during incubation with nalidixic acid.

Authors:  L S McDaniel; L H Rogers; W E Hill
Journal:  J Bacteriol       Date:  1978-06       Impact factor: 3.490

4.  Interactions between twisted DNAs and enzymes: the effects of superhelical turns.

Authors:  J C Wang
Journal:  J Mol Biol       Date:  1974-08-25       Impact factor: 5.469

5.  Induction of the SOS response by new 4-quinolones.

Authors:  I Phillips; E Culebras; F Moreno; F Baquero
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

6.  Ciprofloxacin and antacids.

Authors:  L W Fleming; T A Moreland; W K Stewart; A C Scott
Journal:  Lancet       Date:  1986-08-02       Impact factor: 79.321

7.  Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers.

Authors:  W Brumfitt; I Franklin; D Grady; J M Hamilton-Miller; A Iliffe
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

8.  Membrane potential in anaerobically growing Staphylococcus aureus and its relationship to gentamicin uptake.

Authors:  S M Mates; L Patel; H R Kaback; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Randomized evaluation of ceftazidime or ticarcillin and tobramycin for the treatment of osteomyelitis caused by gram-negative bacilli.

Authors:  T G Sheftel; J T Mader
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora.

Authors:  S Pecquet; A Andremont; C Tancrède
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

View more
  30 in total

1.  Comparative pharmacodynamics of three newer fluoroquinolones versus six strains of staphylococci in an in vitro model under aerobic and anaerobic conditions.

Authors:  David H Wright; Brent W Gunderson; Laurie B Hovde; Gigi H Ross; Khalid H Ibrahim; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Pharmacodynamic modeling of in vitro activity of marbofloxacin against Escherichia coli strains.

Authors:  M Andraud; C Chauvin; P Sanders; M Laurentie
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Functional relationship between bacterial cell density and the efficacy of antibiotics.

Authors:  Klas I Udekwu; Nicholas Parrish; Peter Ankomah; Fernando Baquero; Bruce R Levin
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

4.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

5.  A screen for and validation of prodrug antimicrobials.

Authors:  Laura E Fleck; E Jeffrey North; Richard E Lee; Lawrence R Mulcahy; Gabriele Casadei; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

6.  Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors:  Muhammad Malik; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 7.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

8.  Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones.

Authors:  J D Goldman; D G White; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 9.  Drug interactions and the evolution of antibiotic resistance.

Authors:  Pamela J Yeh; Matthew J Hegreness; Aviva Presser Aiden; Roy Kishony
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633

Review 10.  Quinolone mode of action--new aspects.

Authors:  D C Hooper
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.